# A Trial of Pembrolizumab for Refractory Atypical and Anaplastic Meningioma

> **NCT03016091** · PHASE2 · TERMINATED · sponsor: **Rabin Medical Center** · enrollment: 18 (actual)

## Conditions studied

- Atypical Meningioma
- Anaplastic Meningioma
- Hemangiopericytoma

## Interventions

- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03016091
- **Lead sponsor:** Rabin Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-01-01
- **Primary completion:** 2022-07-01
- **Final completion:** 2022-12-01
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** Slow accrural, dismal results
- **Last updated:** 2025-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03016091

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03016091, "A Trial of Pembrolizumab for Refractory Atypical and Anaplastic Meningioma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03016091. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*